To find a new series of arginine vasopressin (AVP) V1A receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4′-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide (7) was investigated. Replacement of the 2-phenyl group by a 2-ethyl-1H-imidazol-1-yl group was effective in yielding a V1A-selective compound. Moreover, this imidazolyl group was introduced in the same position in YM-35471 (6), and further studies of these compounds were performed. Consequently, we found that the (Z)-4′-(4,4-difluoro-5-[(N-cyclopropylcarbamoyl)methylene]-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl}carbonyl)-2-(2-ethyl-1H-1-imidazol-1-yl)benzanilide (9f) exhibited highly potent affinity and selectivity, and was the most potent antagonist for the V1A receptor among our compounds. The synthesis and pharmacological evaluation of these compounds are described in this paper
为了寻找新的
精氨酸加压素(AVP)V1A受体拮抗剂,研究了2-苯基-4′-[(2,3,4,5-四氢-1H-1-苯并嗪-1-基)羧酰基]苯腈(7)的2-苯基基团的影响。将2-苯基基团替换为2-乙基-
1H-咪唑-1-基基团有效地产生了一个V1A选择性化合物。此外,该
咪唑基团也被引入到YM-35471(6)的相同位置,针对这些化合物进行了进一步研究。因此,我们发现(Z)-4′-(4,4-二
氟-5-[(N-环丙基
氨基)亚甲基]-2,3,4,5-四氢-1H-1-苯并嗪-1-基}羧酰基)-2-(2-乙基-1H-1-
咪唑-1-基)苯腈(9f)表现出高度的亲和力和选择性,是我们化合物中对V1A受体最有效的拮抗剂。本文描述了这些化合物的合成及药理学评估。